A clinical study of WT1 peptide-based cancer vaccine WT1 Trio for myeloproliferative neoplasms
Not Applicable
Recruiting
- Conditions
- myeloproliferative neoplasms (Polycythemia vera, Essential thrombocythemia,Essential thrombocytosis) MPN (PV, ET)
- Registration Number
- JPRN-UMIN000031960
- Lead Sponsor
- Osaka university Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
- >=10% of blasts in the peripheral blood - active infectious disease including tuberculosis. - active autoimmune disease and/or collagen disease -severe complications (grade >=3 according to CTCAE v4.0) - severe mental disorders - participation in other clinical trial which could affect the results of the study - having other malignant disease within three years prior to the registration -Dicided as inadequate by the principal investigator or a subinvestigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Induction of WT1-specific immune responses Clinical efficacy